Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 9/20 | 0.45 |
| ▸ | CCR9 | P51686 | 1/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 2/20 | 0.36 |
| ▸ | CTSB | P07858 | 1/20 | 0.36 |
| ▸ | SYK | P43405 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19252910 | 1.00 | AAK1 (0.45) | AAK1CCR9USP30MCL1PCSK9 | |
| SCHEMBL28664188 | 0.91 | AAK1 (0.44) | AAK1CCR9USP30PCSK9CTSS | |
| SCHEMBL19268458 | 0.91 | AAK1 (0.44) | AAK1CCR9USP30PCSK9CTSS | |
| SCHEMBL5356345 | 0.88 | AAK1 (0.44) | AAK1CCR9USP30PCSK9SYK | |
| SCHEMBL5356339 | 0.88 | AAK1 (0.44) | AAK1CCR9USP30PCSK9SYK | |
| SCHEMBL5762113 | 0.82 | PCSK9 (0.38) | AAK1CCR9PCSK9CTSSCTSK | |
| SCHEMBL27573512 | 0.82 | AAK1 (0.38) | AAK1PCSK9CTSSCTSKCTSB | |
| SCHEMBL19252913 | 0.82 | PCSK9 (0.38) | AAK1CCR9PCSK9CTSSCTSK | |
| SCHEMBL27548104 | 0.82 | MEN1 (0.39) | CCR9PCSK9SYKRXFP1NR1H2 | |
| SCHEMBL27521588 | 0.80 | SERPINE1 (0.35) | AAK1PCSK9CTSSCTSKSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3848373-A1 | N-(1-((HETEROCYCLYL)METHYL)-1H-PYRAZOL-4-YL)-6-OXO-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[L,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | Phoenix Molecular Designs (CA) | 2021-07-14 | — | — | EP | disclosed |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2021-06-24 | — | — | US | disclosed |
| EP-3416964-B1 | 6-OXO-N-(1-(BENZYL)-1H-PYRAZOL-4-YL)-6,7,8,9- TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-A]PYRAZINE-2-CARBOXAMIDE DERIVATIVES AS P90 RIBOSOMAL S6 KINASE (RSK) INHIBITORS FOR TREATING CANCER | PHOENIX MOLECULAR DESIGNS (CA) | 2020-12-16 | — | — | EP | disclosed |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2020-09-01 | — | — | US | disclosed |
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2019-05-09 | — | — | US | disclosed |
| EP-3416964-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | Phoenix Molecular Designs (CA) | 2018-12-26 | — | — | EP | disclosed |
| US-10081632-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGNS (CA) | 2018-09-25 | — | — | US | disclosed |
| US-20170327501-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-11-16 | — | — | US | disclosed |
| US-9771366-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-a]pyrazine-2-carboxamides as RSK inhibitors | PHOENIX MOLECULAR DESIGN (CA) | 2017-09-26 | — | — | US | disclosed |
| WO-2017141116-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | WO | disclosed |
| US-20170240549-A1 | TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | PHOENIX MOLECULAR DESIGNS (CA) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190134029-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA5, RPS6KA2, RPS6KA1 | AAK1 307/4885CCR9 4316/4885USP30 652/4885 |
| US-20170240549-A1 | TETRAHYDROPYRIDO[3',2':4,5]PYRROLO[1,2-a]PYRAZINE-2-CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA5, RPS6KA2, RPS6KA1 | AAK1 130/4885CCR9 4698/4885USP30 941/4885 |
| US-10081632-B2 | Substituted tetrahydropyrido[3′,2′:4,5]pyrrolo[1,2-α]pyrazine-2-carboxamides as RSK inhibitors | RPS6KA2, RPS6KA5, RPS6KA1 | AAK1 264/4885CCR9 4610/4885USP30 1376/4885 |
| US-10758530-B2 | Carboxamide derivatives useful as rsk inhibitors | RPS6KA5, RPS6KA2, RPS6KA1 | AAK1 307/4885CCR9 4316/4885USP30 652/4885 |
| US-20170327501-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA2, RPS6KA5, RPS6KA1 | AAK1 218/4885CCR9 4500/4885USP30 651/4885 |
| US-20210186961-A1 | CARBOXAMIDE DERIVATIVES USEFUL AS RSK INHIBITORS | RPS6KA2, RPS6KA5, RPS6KA1 | AAK1 218/4885CCR9 4500/4885USP30 651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.